Glucagon-Like Peptide-1 (GLP) for CNS/ Neuromusc Dis: 83.3% of denials overturned
In 24 California IMR decisions from 2025 to 2025, reviewers overturned 20 (83.3%). In the last five years: 83.3% of 24. 24 were medical-necessity disputes.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2025 | 24 | 83.3% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 5 | 80.0% | 83.3% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 4 | 50.0% | 83.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Zepbound. Zepbound has been recently approved by the U.S. Food and Drug Administration (FDA) for moderate-to-severe obstructive sleep apnea (OSA). This patient has moderate OSA. Even for patients who use continuous positive airway pressure (CPAP) effectively, there can still be residual issues such as daytime sleepiness, suboptimal …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. Zepbound has been approved by the U.S. Food and Drug Administration for chronic weight management in patients with obesity and is supported by evidence for improving obesity-related conditions, including obstructive sleep apnea. In this case, the patient has been diagnosed with …”
“The physician reviewer found that a patient has requested authorization and coverage for Zepbound for sleep apnea. The U.S. Food and Drug Administration (FDA) approves the use of Zepbound for the treatment of moderate-to-severe obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) greater than 15, in adults with obesity, defined as a body mass index (BMI) of 30 kg/m² …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. This patient is seeking treatment with Zepbound for obesity-related obstructive sleep apnea (OSA). However, the sleep study documented in the records provided is not consistent with a diagnosis of OSA. The provided sleep study indicated an apnea-hypopnea index (AHI) of only …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Glucagon-Like Peptide-1 (GLP) denials for CNS/ Neuromusc Dis overturned?
In 24 California IMR decisions from 2025 to 2025, reviewers overturned 20 (83.3%). In the last five years: 83.3% of 24. 24 were medical-necessity disputes.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.